期刊文献+

四川东北地区353株鲍曼不动杆菌的临床分布及耐药性分析 被引量:5

原文传递
导出
摘要 目的了解四川东北地区鲍曼不动杆菌医院内感染分布特点及耐药性。方法采用德灵NC卡和Vitek-32型全自动微生物鉴定和药敏系统对该地区临床分离的353株鲍曼不动杆菌进行鉴定和药敏试验。结果鲍曼不动杆菌临床上主要引起呼吸道感染,在各科室中以ICU检出率最高。该菌仅对亚胺培南较为敏感(82.4%),对其余多种抗生素耐药率高。结论鲍曼不动杆菌是四川东北地区ICU病房和呼吸道感染的重要病原菌,对除碳青霉烯类外的常用抗菌药物呈现多重耐药,必须引起临床高度重视。
出处 《中华临床医师杂志(电子版)》 CAS 2010年第7期1077-1079,共3页 Chinese Journal of Clinicians(Electronic Edition)
基金 国家自然科学基金(30973662)
  • 相关文献

参考文献8

  • 1陈民钧,王辉,中国医院内病原菌耐药监测网.中国重症监护病房革兰阴性菌耐药性连续7年监测研究[J].中华医学杂志,2003,83(5):375-381. 被引量:504
  • 2Lin L;Ling BD;Li XZ.Distribution of the multidrug efflux pump genes,adeABC,adeDE and adeIJK,and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex[J],2009(01).
  • 3Pimentel JD;Low J;Styles K.Control of an outbreak of multi-drug-resistant Acinetobacter baumannii in an intensive care unit and a surgical ward[J],2005(03).
  • 4Bou G;Oliver A;Martinez-Beltran J.OXA-24,a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain[J],2000(06).
  • 5Bou G;Cervero G;Dominguez MA.Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme; high-level carbapenem resistance in A.baumannii is not due solely to the presence of beta-lactamases,2000(09).
  • 6程曦,曾蔚,贾文祥.鲍氏不动杆菌耐药的主要机制[J].国外医药(抗生素分册),2003,24(2):63-64. 被引量:55
  • 7Yoon J;Urban C;Terzian C.In vitro double and triple synergistic activities of Polymyxin B,lmipenem and rifampin against multidrug-resistant Acinetobacter baumannii[J],2004(03).
  • 8施新革,侯文根,董玉珍,梁秋冬.骨科Ⅰ类切口人工内置物手术预防应用抗菌药物对照研究[J].中华临床医师杂志(电子版),2011,5(13):3906-3908. 被引量:4

二级参考文献20

  • 1邓健康,林芳,郭晓兰,凌保东.四川东北地区353株鲍曼不动杆菌的临床分布及耐药性分析[J].中华临床医师杂志(电子版),2010,4(7):1077-1079. 被引量:5
  • 2无.围手术期预防应用抗菌药物指南[J].中华外科杂志,2006,44(23):1594-1596. 被引量:843
  • 3[1]Brisse S, Milatovic D, Fluit A C. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp using automated ribotyping [J]. J Clin Microbiol, 2000,38 (10): 3636
  • 4[2]Afzal-Shah M, Livermore D M. Worldwide emergence of carbapenem-resistant Acinetobacter spp[J] . J Antimicrob Chemother , 1998,41:576
  • 5[3]Robert E W. Resistant mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria [J]. Clin Infect Dis, 1998,27(Suppll): S93
  • 6[4]Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain [J]. Antimicrob Agents Chemother, 2000,44(6):1556
  • 7[5]Fernandez-viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumanniiwith intraventricular colistim sulfomethate sodium[J].Clin Infect Dis, 1999,28(4) :916
  • 8Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 9Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
  • 10Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.

共引文献558

同被引文献35

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部